Keebeck Wealth Management Makes New Investment in Stryker Corporation $SYK

Key Points

• Keebeck Wealth Management initiated a Stryker position by purchasing 9,710 shares worth approximately $3.1 million in the second quarter. Institutional investors collectively own about 77.1% of the medical technology company.
• Stryker reported quarterly earnings of $3.69 per share on $6.59 billion in revenue, exceeding estimates, with revenue rising 9.4% year over year. The company maintained its fiscal 2026 EPS guidance of $14.95–$15.10 and declared a quarterly dividend of $0.88.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $386.28, although several firms recently lowered their targets. Insider selling—including substantial sales by company executives and directors—has added a cautionary signal.

Keebeck Wealth Management purchased a new position in shares of Stryker Corporation (NYSE:SYK - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 9,710 shares of the medical technology company's stock, valued at approximately $3,066,000.

Several other institutional investors have also bought and sold shares of the company. Norges Bank bought a new position in Stryker during the fourth quarter valued at $1,822,272,000. Auto Owners Insurance Co raised its stake in shares of Stryker by 35,047.0% in the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company's stock valued at $1,024,444,000 after buying an additional 2,906,448 shares during the period. Flossbach Von Storch SE purchased a new position in shares of Stryker during the 2nd quarter valued at $464,506,000. Wellington Management Group LLP lifted its position in shares of Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company's stock valued at $2,282,192,000 after buying an additional 1,198,665 shares during the last quarter. Finally, Corient Private Wealth LLC grew its stake in shares of Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company's stock worth $887,525,000 after acquiring an additional 1,146,998 shares during the period. Hedge funds and other institutional investors own 77.09% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SYK. Wolfe Research cut Stryker from an "outperform" rating to a "peer perform" rating in a research note on Thursday, August 13th. Piper Sandler reduced their target price on shares of Stryker from $420.00 to $390.00 and set an "overweight" rating for the company in a research note on Friday, July 31st. JPMorgan Chase & Co. lowered their price target on shares of Stryker from $400.00 to $350.00 and set an "overweight" rating on the stock in a research report on Friday, July 31st. Wells Fargo & Company dropped their price target on shares of Stryker from $456.00 to $418.00 and set an "overweight" rating on the stock in a research note on Friday, May 1st. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 price objective on shares of Stryker in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $386.28.

Insider Activity

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of the firm's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares of the company's stock, valued at approximately $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 665,370 shares of company stock worth $216,238,501. 4.60% of the stock is owned by company insiders.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Stryker Stock Performance

Shares of SYK opened at $329.86 on Friday. The stock's 50-day simple moving average is $326.99 and its 200 day simple moving average is $332.64. The stock has a market capitalization of $126.52 billion, a price-to-earnings ratio of 34.18, a price-to-earnings-growth ratio of 2.09 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm's revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the company earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts forecast that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is 36.48%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source